| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a998f8ffdbe80bf754a93422e166156d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74d27214bca307922ec575c04828ca77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_864d2e26a096e56f38ce5b14f47c15a8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-735
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2010-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63a6e19aa5a0f37d58654f81f6296f47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99c7480eda678482956ef4a6212e1067 |
| publicationDate |
2011-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2011027916-A1 |
| titleOfInvention |
Therapeutic agent for allergic diseases |
| abstract |
Disclosed are: an inhibitor of the IgE-dependent activation of mast cells; a method for inhibiting the the IgE-dependent activation of mast cells; a pharmaceutical composition for treating and/or preventing allergic diseases; a method for treating and/or preventing allergic diseases; a phosphorylated peptide which can be used for the inhibitors and the methods; and others. The inhibitor of the IgE-dependent activation of mast cells is characterized by comprising a peptide (a) or (b), a derivative of the peptide, or a salt of the peptide or the derivative: (a) a peptide which comprises the amino acid sequence represented by formula (I): KVPEDRV-Y1-EELNI-Y2-SAT-Y3-SELEDPG; and (b) a peptide which is produced by deleting, substituting or adding one or several amino acid residues in the amino acid sequence represented by formula (I) and which has an inhibitory activity on the IgE-dependent activation of mast cells. |
| priorityDate |
2009-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |